|
EconStor >
ZBW - Deutsche Zentralbibliothek für Wirtschaftswissenschaften / Leibniz-Informationszentrum Wirtschaft >
Intereconomics - Review of European Economic Policy >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10419/42042
|
| | |
Full metadata record
| DC Field | | Value | | Language |
| dc.contributor.author | | Boscheck, Ralf | | en_US |
| dc.date.accessioned | | 2010-12-01T09:41:31Z | | - |
| dc.date.available | | 2010-12-01T09:41:31Z | | - |
| dc.date.issued | | 2008 | | en_US |
| dc.identifier.citation | | Intereconomics 0020-5346 43 2008 5 277-281 | | en_US |
| dc.identifier.pi | | doi:10.1007/s10272-008-0261-z | | - |
| dc.identifier.uri | | http://hdl.handle.net/10419/42042 | | - |
| dc.language.iso | | eng | | en_US |
| dc.subject.ddc | | 330 | | en_US |
| dc.subject.stw | | Arzneimittelrecht | | en_US |
| dc.subject.stw | | Verbraucherschutz | | en_US |
| dc.subject.stw | | Pharmazeutisches Produkt | | en_US |
| dc.subject.stw | | Deregulierung | | en_US |
| dc.subject.stw | | Gesundheitswesen | | en_US |
| dc.subject.stw | | USA | | en_US |
| dc.subject.stw | | Deutschland | | en_US |
| dc.title | | Off-label drugs vs. the merits of centralised regulatory control | | en_US |
| dc.type | | Article | | en_US |
| dc.identifier.ppn | | 582112257 | | en_US |
| dc.rights | | http://www.econstor.eu/dspace/Nutzungsbedingungen | | en_US |
| Appears in Collections: | | Intereconomics - Review of European Economic Policy
|
Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.
|